Treatment with beta-blocker nebivolol ameliorates oxidative stress and endothelial dysfunction in tenofovir-induced nephrotoxicity in rats
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Citação
FRONTIERS IN MEDICINE, v.9, article ID 953749, 15p, 2022
Resumo
BackgroundTenofovir disoproxil fumarate (TDF), a widely prescribed component in antiretroviral regimens, has been associated with nephrotoxicity. Nebivolol is a third generation selective beta-1 adrenergic receptor blocker and may protect renal structure and function through the suppression of oxidative stress and enhancement of nitric oxide (NO) synthesis. We aimed to investigate whether nebivolol could be an effective therapeutic strategy to mitigate tenofovir-induced nephrotoxicity. MethodsWe allocated Wistar rats to four groups: control (C), received a standard diet for 30 days; NBV, received a standard diet for 30 days added with nebivolol (100 mg/kg food) in the last 15 days; TDF, received a standard diet added with tenofovir (300 mg/kg food) for 30 days; and TDF+NBV, received a standard diet added with tenofovir for 30 days and nebivolol in the last 15 days. ResultsLong-term exposure to tenofovir led to impaired renal function, induced hypertension, endothelial dysfunction and oxidative stress. Nebivolol treatment partially recovered glomerular filtration rate, improved renal injury, normalized blood pressure and attenuated renal vasoconstriction. Administration of nebivolol contributed to reductions in asymmetric dimethylarginine (ADMA) levels as well as increases in endothelial nitric oxide sintase (eNOS) accompanied by renin-angiotensin-aldosterone system downregulation and decreases in macrophage and T-cells infiltrate. Furthermore, nebivolol was responsible for the maintenance of the adequate balance of thiobarbituric acid reactive substances (TBARS) and glutathione (GSH) levels and it was associated with reductions in NADPH oxidase (NOX) subunits. ConclusionNebivolol holds multifaceted actions that promote an advantageous option to slow the progression of kidney injury in tenofovir-induced nephrotoxicity.
Palavras-chave
tenofovir, nephrotoxicity, nebivolol, hypertension, endothelium dysfunction, oxidative stress
Referências
- Rosei EA, 2007, DRUGS, V67, P1097
- Alan C, 2016, INT BRAZ J UROL, V42, P614, DOI 10.1590/S1677-5538.IBJU.2015.0030
- Bakris G, 2005, HYPERTENSION, V46, P473, DOI 10.1161/01.HYP.0000178188.29446.48
- Blumenfeld JD, 1999, AM J HYPERTENS, V12, P451, DOI 10.1016/S0895-7061(99)00005-9
- BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
- Canale D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103055
- Coats A, 2017, J HUM HYPERTENS, V31, P376, DOI 10.1038/jhh.2017.8
- de Braganca AC, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12331
- Deneva-Koycheva Tanya I, 2011, Folia Med (Plovdiv), V53, P28
- Dursun M, 2018, BRATISL MED J, V119, P718, DOI 10.4149/BLL_2018_128
- Encinas JFA, 2021, EUR J PHARMACOL, V905, DOI 10.1016/j.ejphar.2021.174180
- Feeney Eoin R, 2011, Open Cardiovasc Med J, V5, P49, DOI 10.2174/1874192401105010049
- Fernandez-Fernandez B, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/354908
- Fongemie J, 2015, DRUGS, V75, P1349, DOI 10.1007/s40265-015-0435-5
- Gandhi C, 2008, RENAL FAILURE, V30, P921, DOI 10.1080/08860220802353900
- Gois PHF, 2016, FREE RADICAL BIO MED, V101, P176, DOI 10.1016/j.freeradbiomed.2016.10.012
- Goncalves JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107228
- Habibi J, 2011, ENDOCRINOLOGY, V152, P659, DOI 10.1210/en.2010-1038
- Hewedy WA, 2016, PHARMACOL REP, V68, P1319, DOI 10.1016/j.pharep.2016.08.009
- Izzedine H, 2005, AM J KIDNEY DIS, V45, P804, DOI 10.1053/j.ajkd.2005.02.010
- Jafari A, 2014, EUR J CLIN PHARMACOL, V70, P1029, DOI 10.1007/s00228-014-1712-z
- Jao J, 2010, ADV CHRONIC KIDNEY D, V17, P72, DOI 10.1053/j.ackd.2009.07.009
- Kim HJ, 2011, J PHARMACOL EXP THER, V337, P583, DOI 10.1124/jpet.110.175828
- Kim HJ, 2010, AM J PHYSIOL-RENAL, V298, pF662, DOI 10.1152/ajprenal.00421.2009
- Kitada M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00755
- Lancas T, 2011, RESPIRATION, V82, P177, DOI 10.1159/000326897
- Liborio AB, 2008, KIDNEY INT, V74, P910, DOI 10.1038/ki.2008.252
- Mingzhao S, 2020, WHO VACC PREV DIS MO
- Miyaji T, 2001, J AM SOC NEPHROL, V12, P900, DOI 10.1681/ASN.V125900
- Moningka NC, 2012, NEPHROL DIAL TRANSPL, V27, P913, DOI 10.1093/ndt/gfr449
- Morsy MA, 2016, BASIC CLIN PHARMACOL, V118, P449, DOI 10.1111/bcpt.12538
- Mustafi SB, 2009, CELL STRESS CHAPERON, V14, P579, DOI 10.1007/s12192-009-0109-x
- Olawi N, 2019, BASIC CLIN PHARMACOL, V125, P189, DOI 10.1111/bcpt.13248
- Ozyildiz AG, 2017, J CARDIOVASC PHARM T, V22, P65, DOI 10.1177/1074248416644987
- Patzak A, 2007, CURR OPIN NEPHROL HY, V16, P46, DOI 10.1097/MNH.0b013e328011a89b
- Ramkumar N, 2013, CURR OPIN NEPHROL HY, V22, P32, DOI 10.1097/MNH.0b013e328359dbed
- SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4
- Shi S, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181614
- Soler-Palacin P, 2011, AIDS, V25, P171, DOI 10.1097/QAD.0b013e328340fdca
- Sun D, 2012, LIFE SCI, V90, P900, DOI 10.1016/j.lfs.2012.04.018
- Toblli JE, 2011, J HYPERTENS, V29, P1613, DOI 10.1097/HJH.0b013e328349064c
- Toprak O, 2008, NEPHROL DIAL TRANSPL, V23, P853, DOI 10.1093/ndt/gfm691
- Tzemos N, 2001, CIRCULATION, V104, P511, DOI 10.1161/hc3001.094207
- Vogt BL, 2007, BIOCHEM PHARMACOL, V73, P1613, DOI 10.1016/j.bcp.2007.01.033
- Wang Y, 2018, PHARMACOL REP, V70, P917, DOI 10.1016/j.pharep.2018.04.004
- Wang Y, 2018, CLIN EXP PHARMACOL P, V45, P1135, DOI 10.1111/1440-1681.13001
- Whaley-Connell A, 2009, AM J NEPHROL, V30, P354, DOI 10.1159/000229305
- Winiarska K, 2016, J PINEAL RES, V60, P109, DOI 10.1111/jpi.12296
- Yazie TS, 2020, DRUG HEALTHC PATIENT, V12, P245, DOI 10.2147/DHPS.S283402
- Yonova DTI., 2018, NEPHROL RENAL DIS, V3, P1, DOI [10.15761/NRD.1000147, DOI 10.15761/NRD.1000147]
- Younis NN, 2020, J PHARM PHARMACOL, V72, P1546, DOI 10.1111/jphp.13340
- Zoja C, 2014, NEPHROL DIAL TRANSPL, V29, pI19, DOI 10.1093/ndt/gft224